Monkey trial: Prof Stephen Evans at the London School of Hygiene and Tropical Medicine calls it as “high quality” and “very encouraging”


While breastmilk is being tested for a cure and a blacklight experiment is being initiated to detect the global prevailing virus, a vaccine now happens to provide protection against the global pandemic in six rhesus macaque monkeys.

Just like the chloroquine, this vaccine, however, does not provide any guarantee for complete treatment but to some extent, it will apparently offer some relief.

This vaccine was firstly initiated in six rhesus macaque monkeys. They were exposed to the SARS-CoV-2 virus and were vaccinated. After this trial, there was less of the virus in their lungs. This test was initiated on a pilot basis in the United States, involving researchers from the US government’s National Institutes of Health and from the University of Oxford.

The monkeys responded positively to this trial as the vaccine seemed to protect them from developing pneumonia. Dr Kathryn Edwards (Vanderbilt University) says “We need to know that it protects the animal or the human from the infection.”

Now it is being experienced in human clinical trials as rhesus macaques have the same immune system as human beings. Although the final verdict has not been summoned yet, Prof Stephen Evans at the London School of Hygiene and Tropical Medicine calls it as “high quality” and “very encouraging”.

For the time being, more than one thousand volunteers are undergoing this test through the University of Oxford and more than one hundred experimental coronavirus vaccines are being developed. The idea behind this is that by injecting the virus, the body recognizes part of it after which it produces antibodies to fight it off.

The vaccine consists of genetic material from the coronavirus and once it is injected into a patient it triggers an immune response, thus preparing the body to overcome a future disease. The vaccine relies on a cold virus that is modified so that the infection is not spread.